Long-term Observational Study Of Shenxian Shengmai Oral Liquid In The Treatment Of Mild To Moderate Symptomatic Bradyarrhythmia

Objective:Previous observational studies have shown that Shenxian Shengmai Oral Liquid has obvious clinical effects on bradyarrhythmia,but due to the lack of long-term systematic comparison research,its clinical application is limited.In this study,Shenxian Shengmai Oral Liquid was used to treat patients with mild to moderate symptomatic bradyarrhythmia without syncope.The subjective symptom scores and the results of objective auxiliary examinations before and after treatment were compared to objectively evaluate its long-term efficacy and impact on the quality of patients’ life.It provides experimental basis and theoretical support for the clinical application of Shenxian Shengmai Oral Liquid and opens up a new way for the clinical treatment of patients with bradyarrhythmia.Methods:A selection of 156 patients with bradyarrhythmia who attended Northern Jiangsu People’s Hospital from July 2018 to December 2019 were randomly divided into a treatment group of 80 cases and a control group of 76 cases according to different treatment plans.These patients had chest tightness,fatigue,or dizziness.But no syncope occurred,and these symptoms are clearly related to bradycardia.80 cases in the treatment group were treated with Shenxian Shengmai Oral Liquid,and 76 cases in the control group were treated with Xinbao Pills.All the patients were followed up every 2 months over a period of 12 months.Collecting and comparing general information,TCM syndrome scores,Holter monitor test recordings,blood routine and biochemical examination results of patients before and after treatment.Results:1.There was no statistical difference between the two groups of patients in terms of average age,gender,history of hypertension,history of diabetes,history of coronary heart disease,types of bradyarrhythmia,and concomitant medications(p>0.05).2.The self-control results of the treatment group showed that Shenxian Shengmai Oral Liquid treatment can significantly increase the patient’s average heart rate and slowest heart rate(p<0.05),and reduce the TCM syndrome scores(p<0.05).The self-control results of the control group showed that Xinbao Pills treatment can reduce the patient’s TCM syndrome scores(p<0.05),but the improvement of the patient’s average heart rate and slowest heart rate was not significant(p>0.05).3.The analysis between groups showed that the total effective rate of Holter(65.0%vs 42.1%,p<0.05)and the total effective rate of TCM symptoms(73.8%vs 56.6%,p<0.05)in the treatment group were significantly higher than those of the control group.4.The treatment group was further divided into two subgroups,sick sinus syndrome and atrioventricular block,according to the types of bradycardia.The total effective rate of Holter was 79.5%in the group with sick sinus syndrome and 53.3%in the group with atrioventricular block.The total effective rate of Holter in the group with sick sinus syndrome was higher than that in the group with atrioventricular block(p<0.05).5.According to the 24-hour average heart rate,the treatment group was further divided into two subgroups:mild bradycardia(50-59 beats/min)and moderate bradycardia(40-49 beats/min).The total effective rate of Holter was 66.1%in the mild group and 33.3%in the moderate group.The total effective rate of Holter in the mild group is higher than that in the moderate group(p<0.05).6.After treatment with Shenxian Shengmai Oral Liquid,There was no statistical difference in the number of Premature beats,Blood pressure,Hemoglobin(HGB),Platelet count(PLT),White blood cell count(WBC),Creatinine(CRE),Alanine aminotransferase(ALT)and Aspartate aminotransferase(AST)(p>0.05).Conclusions:1.Shenxian Shengmai Oral Liquid has a good clinical effect on patients with bradyarrhythmia,which can significantly increase the average heart rate and the slowest heart rate of patients,and improve clinical symptoms;2.The results of subgroup analysis showed that in patients with sick sinus syndrome and mild bradycardia,the clinical benefit of Shenxian Shengmai Oral Liquid was more obvious;3.In this study,Shenxian Shengmai Oral Liquid had no obvious side effects,and its clinical application safety was good.